Holen Sie sich die Stockscreener-App
1.565
2.80%
-0.045
Schlusskurs vom Vortag:
$1.61
Offen:
$1.6
24-Stunden-Volumen:
2.42M
Relative Volume:
2.13
Marktkapitalisierung:
$99.00M
Einnahmen:
$139.77M
Nettoeinkommen (Verlust:
$-97.62M
KGV:
-0.9905
EPS:
-1.58
Netto-Cashflow:
$-61.71M
1W Leistung:
+10.99%
1M Leistung:
+1.62%
6M Leistung:
+14.23%
1J Leistung:
-51.25%
1-Tages-Spanne:
$1.53
$1.66
1-Wochen-Bereich:
$1.32
$1.66
52-Wochen-Spanne:
$0.9897
$3.60
Macrogenics Inc Stock (MGNX) Company Profile
Firmenname
Macrogenics Inc
Sektor
Branche
Telefon
301-251-5172
Adresse
9704 MEDICAL CENTER DRIVE, Rockville, MD
Vergleichen Sie MGNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.565 | 101.85M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.58 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.45 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
849.65 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
395.60 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
164.53 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2024-11-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-31 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-05-10 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-04-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-03-04 | Bestätigt | BTIG Research | Buy |
| 2024-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-22 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-11-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-02-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-04 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Hochstufung | Barclays | Underweight → Overweight |
| 2020-12-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2019-12-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Guggenheim | Neutral |
| 2019-02-07 | Hochstufung | Citigroup | Sell → Buy |
| 2019-02-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-02-06 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-12-10 | Herabstufung | Raymond James | Outperform → Underperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-05-31 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-31 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Macrogenics Inc Aktie (MGNX) Neueste Nachrichten
Is MacroGenics Inc. stock a dividend growth opportunityJuly 2025 Action & Weekly Market Pulse Alerts - Улправда
MacroGenics Insider Ups Holding By 909% During Year - simplywall.st
Analyzing MacroGenics Stock: To Buy Or Wait? - StocksToTrade
EcoR1 Capital LLC Purchases New Shares in MacroGenics, Inc. $MGNX - MarketBeat
Will MacroGenics Inc stock attract more institutional investorsRecession Risk & Real-Time Volume Triggers - moha.gov.vn
MacroGenics (NASDAQ:MGNX) Stock Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
Reviewing MacroGenics (NASDAQ:MGNX) & Exagen (NASDAQ:XGN) - Defense World
Wall Street analysts’ outlook for Macrogenics Inc (MGNX) - setenews.com
What analysts say about MacroGenics Inc stockReal-Time Stock Alerts & Free Tremendous Portfolio Expansion - earlytimes.in
MacroGenics (NASDAQ:MGNX) Shares Cross Below 200-Day Moving AverageHere's What Happened - MarketBeat
MacroGenics (NASDAQ:MGNX) Shares Cross Below 200-Day Moving Average – Here’s What Happened - Defense World
IM Cannabis (NASDAQ:IMCC) & MacroGenics (NASDAQ:MGNX) Head to Head Survey - Defense World
Macrogenics (MGNX) Stock Analysis Report | Financials & Insights - Benzinga
MGNX (Macrogenics) EPS without NRI : $-1.20 (TTM As of Sep. 2025) - GuruFocus
MGNX (Macrogenics) Operating Cash Flow per Share : $-2.58 (TTM As of Sep. 2025) - GuruFocus
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference - Enidnews.com
Taking the lead: Macrogenics Inc (MGNX) - Setenews
MacroGenics (Nasdaq: MGNX) to Present at 8th Evercore Healthcare Conference Fireside Chat - Stock Titan
Is MacroGenics Inc. stock cheap at current valuationEarnings Recap Summary & High Conviction Buy Zone Picks - newser.com
Is MacroGenics Inc. stock positioned for digital transformation2025 AllTime Highs & Daily Volume Surge Trade Alerts - newser.com
Will MacroGenics Inc. stock recover faster than peersForecast Cut & Free Growth Oriented Trading Recommendations - newser.com
MacroGenics Announces Departure of Chief Medical Officer - The Globe and Mail
Why MacroGenics Inc. stock attracts high net worth investorsGap Up & Weekly Setup with High ROI Potential - newser.com
Is MacroGenics Inc. stock attractive for passive investorsLong Setup & Expert Verified Movement Alerts - newser.com
Will MacroGenics Inc. stock continue dividend increasesEarnings Recap Report & Long-Term Safe Investment Plans - newser.com
What MACD and RSI say about MacroGenics Inc.2025 Year in Review & Risk Managed Investment Entry Signals - newser.com
Automated trading signals detected on MacroGenics Inc.Inflation Watch & Safe Entry Point Identification - newser.com
Ranking MacroGenics Inc. among high performing stocks via toolsSell Signal & Community Consensus Trade Alerts - newser.com
Will MacroGenics Inc. stock recover after recent drop2025 Technical Overview & Safe Capital Growth Tips - newser.com
Comparing MacroGenics Inc. in custom built stock radarsJuly 2025 Highlights & AI Forecast Swing Trade Picks - newser.com
United States Bispecific T-cell Engagers (BiTEs) Market Size, - openPR.com
Finanzdaten der Macrogenics Inc-Aktie (MGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):